Biotechnology News

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic...

Highlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA)New U.S. composition of matter patent granted...

Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as...

Le TGM-148 est conçu pour associer une efficacité hémostatique à un profil de sécurité favorable et une faible contrainte thérapeutique Le deuxième actif de Tangram à entrer en phase clinique en...

TGM-148 wurde entwickelt, um hämostatische Wirksamkeit mit einem günstigen Sicherheitsprofil und einer geringen Behandlungsbelastung zu verbinden Zweites Präparat von Tangram, tritt 2026 in klinische...

This international award, honoring “the best of the best” in medical innovation, represents yet another important external recognition of AI-Immunology™ COPENHAGEN, Denmark, October 30, 2026 -...

REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee...

Nephros Schedules Third Quarter 2026 Financial Results Conference Call

FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following...

WEST PALM BEACH, FL, Oct. 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “Company”) today announced that it has entered into Stock Purchase Agreements to acquire...